...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Transfer of ZEN from RBC DI to TFSA

Although it wasn't you albertaclipper, you are facing the same scenario this other individual is.  And rvxoldtimer you are correct, fv as opposed to fmv.  The one I submitted was from Zeniths website under faq's.  Dated Feb 2019, it was the fv as of mid Oct 2018.  I am thinking in my case it was accepted as it was within 6 months of issuance.  It is highly frustrating without a doubt.

Share
New Message
Please login to post a reply